Durham, NC, United States of America

Andrew Scribner

This inventor holds 12 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Roivant Sciences Gmbh, Merial Limited, Scynexis, Inc.. Active years: 2002-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Scribner. Retrieved from https://idiyas.com/inventor/andrew-scribner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 58.3


 

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 49(Granted Patents)


Company Filing History:


Years Active: 2002-2023

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Spirocyclic Compounds
Tryptophan Hydroxylase Inhibitors
Macrocycles
Cyclic Peptides
Pesticidal Compounds
5-Substituted-Alkylaminopyrazole
Pesticides
Compositions
12 patents (USPTO):Explore Patents

Title: Unveiling Inventor Andrew Scribner's Legacy in the World of Pharmaceuticals

Introduction:

Andrew Scribner, a prolific inventor based in Durham, NC, has made significant contributions to the field of pharmaceuticals with a total of 12 patents to his name. His groundbreaking work has focused on spirocyclic compounds as tryptophan hydroxylase inhibitors, showcasing his dedication to advancing treatments for a diverse range of diseases and disorders associated with peripheral serotonin.

Latest Patents:

Scribner's latest patents center around spirocyclic compounds as tryptophan hydroxylase inhibitors, specifically targeting isoform 1 (TPH1). These compounds have shown promise in the treatment of various conditions such as gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, low bone mass diseases, serotonin syndrome, and cancer. His innovative approach underscores a commitment to improving patient outcomes and addressing unmet medical needs.

Career Highlights:

Throughout his career, Andrew Scribner has been associated with renowned companies in the pharmaceutical industry. He has contributed his expertise to Roivant Sciences GmbH and Scynexis, Inc., where his research and inventions have paved the way for novel therapeutic interventions. Scribner's resilience and passion for innovation have been instrumental in shaping the landscape of pharmaceutical advancements.

Collaborations:

In his pursuit of scientific excellence, Andrew Scribner has collaborated with esteemed professionals in the field. Notable coworkers include Stéphane De Lombaert and Daniel R Goldberg, who have worked alongside Scribner to bring his visionary ideas to fruition. These collaborations have fueled creativity and fostered a spirit of teamwork essential for driving progress in pharmaceutical research.

Conclusion:

Andrew Scribner's remarkable journey as an inventor heralds a new era of possibilities in pharmaceutical innovation. His relentless pursuit of scientific discovery and unwavering commitment to improving healthcare outcomes underscore the profound impact of his work. As he continues to push boundaries and challenge conventions, Scribner stands as a beacon of inspiration for aspiring inventors and researchers worldwide, leaving an indelible mark on the realms of patents and inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…